Basic information
- CAS
19716-56-4- Standard SMILES
c1ccc(CC2NCCc3ccccc32)cc1- InChIKey
YRYCIFUZSUMAAY-UHFFFAOYSA-N- Molecular formula
- C16H17N
- Average molar mass
- 223.31 g/mol
- Monoisotopic mass
- 223.13609954
Overview
(RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline is a benzyltetrahydroisoquinoline. It is a conjugate base of a 1-benzyl-1,2,3,4-tetrahydroisoquinolin-2-ium.
Names & identifiers
- Preferred name
- 1-Benzyl-1,2,3,4-Tetrahydroisoquinoline
- IUPAC
- 1-benzyl-1,2,3,4-tetrahydroisoquinoline
- English name
- 1-Benzyl-1,2,3,4-tetrahydroisoquinoline
- Molecular formula
- C16H17N
- Molecular weight
- 223.31
Names & synonyms
Show more names
Database identifiers
- CAS
19716-56-4- PubChem CID
- 98468
- DTXSID
DTXSID70864898- ChEMBL
CHEMBL21640- ChEBI
CHEBI:16804- UNII
- X4S06GK4KN
- Nikkaji
- J432.285A
Properties
Computed structural properties
- XLogP
- 3.3
- Topological polar surface area
- 12 Ų
- Hydrogen bond donors
- 1
- Hydrogen bond acceptors
- 1
- Rotatable bonds
- 2
- Heavy atoms
- 17
- Formal charge
- 0
- Complexity
- 232
Experimental & physicochemical properties
Physicochemical properties
- Boiling point
- 120 °C · 120 °C(Press: 0.005 Torr)
- Density
- 1.06 · 1.060±0.06 g/cm3(Predicted)
- pka
- 9.66 · 9.66±0.40(Predicted)
- FDA UNII
- 4 S06GK4KN · X4S06GK4KN
- Symbol(GHS)
- 7 · GHS07
- Signal word
- Warning
- Hazard statements
- 315 · H315-H319-H335
- Precautionary statements
- 280 · P280-P261
- HazardClass
- IRRITANT
- HS Code
- 2933499090 · 2933499090
Safety & regulation
Safety data
- hs_code
- 2933499090
- Signal word
- Warning
- Symbol(GHS)
- GHS07
- hazard_class
- IRRITANT
- Hazard statements
- H315-H319-H335
- Precautionary statements
- P280-P261
Chemistry & industry
Pharmacology
MeSH Pharmacological Classification
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
Applications
Uses1-Benzyl-1,2,3,4-tetrahydro-isoquinoline is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Parkinson's Disease[1][2].
Suppliers16 total
Additional notes
DefinitionChEBI: (RS)-1-benzyl-1,2,3,4-tetrahydroisoquinoline is a benzyltetrahydroisoquinoline. It is a conjugate base of a 1-benzyl-1,2,3,4-tetrahydroisoquinolin-2-ium.
Related reactions
Compound notes
Loading…